In addition, in leukocytes from PD patients, hypomethylation of NPAS2 (neuronal PAS domain protein 2) [57] and DRD2 (dopamine receptor D2) [57] has been proposed as a novel biomarker for PD. This evidence concerns the gene NPAS2 and Parkinson disease.